Resultados globales: 10 registros encontrados en 0.02 segundos.
Artículos, Encontrados 7 registros
Documentos de investigación, Encontrados 3 registros
Artículos Encontrados 7 registros  
1.
10 p, 1.3 MB Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy / Floros, Konstantinos V. (Philips Institute for Oral Health Research) ; Lochmann, Timothy L. (Philips Institute for Oral Health Research) ; Hu, Bin (Virginia Commonwealth University School of Medicine) ; Monterrubio, Carles (Memorial Sloan Kettering Cancer Center) ; Hughes, Mark T. (Philips Institute for Oral Health Research) ; Wells, Jason D. (Norris Cotton Cancer Center) ; Morales, Cristina Bernadó (Vall d'Hebron Institut d'Oncologia) ; Ghotra, Maninderjit S. (Philips Institute for Oral Health Research) ; Costa, Carlotta (Massachusetts General Hospital) ; Souers, Andrew J. (AbbVie Inc) ; Boikos, Sosipatros A. (Virginia Commonwealth University) ; Leverson, Joel D. (AbbVie Inc) ; Tan, Ming (University of South Alabama) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ; Koblinski, Jennifer E. (Virginia Commonwealth University School of Medicine) ; Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Paré, Laia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Miller, Todd W. (Norris Cotton Cancer Center) ; Dozmorov, Mikhail G. (Virginia Commonwealth University) ; Harada, Hisashi (Philips Institute for Oral Health Research) ; Windle, Brad E. (Philips Institute for Oral Health Research) ; Scaltriti, Maurizio (Memorial Sloan Kettering Cancer Center) ; Faber, Anthony C. (Philips Institute for Oral Health Research)
In HER2 -amplified breast cancers, HER2 inhibitors have been very successful as adjuvant therapy but not as monotherapy. Here, we demonstrate that coamplification of a HER2 intronic miRNA causes intrinsic resistance to HER2 inhibitors by indirectly down-regulating the pro-apoptotic NOXA. [...]
2018 - 10.1073/pnas.1717820115
Proceedings of the National Academy of Sciences of the United States of America, Vol. 115 (february 2018) , p. E2594-E2603  
2.
13 p, 2.0 MB Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer / Garrido-Castro, Ana C. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Saura, Cristina (SOLTI Breast Cancer Research Group, Barcelona) ; Barroso-Sousa, Romualdo (Present Address: Hospital Sírio-Libanês, Brasilia, Brazil) ; Guo, Hao (Dana-Farber Cancer Institute. Division of Biostatistics, Department of Data Sciences) ; Ciruelos, Eva (Hospital Universitario 12 de Octubre (Madrid)) ; Bermejo, Begoña (CIBERONC-ISCIII. Clinic University Hospital, INCLIVA Biomedical Research Institute) ; Gavilá, Joaquin (Fundación Instituto Valenciano De Oncología) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ; Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Paré, Laia (SOLTI Breast Cancer Research Group) ; Céliz, Pamela (SOLTI Breast Cancer Research Group) ; Villagrasa, Patricia (SOLTI Breast Cancer Research Group) ; Li, Yisheng (The University of Texas MD Anderson Cancer Center. Department of Biostatistics, Division of Basic Sciences) ; Savoie, Jennifer (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Xu, Zhan (Northern Arizona University. School of Communication) ; Arteaga, Carlos L. (UT Southwestern Medical Center. Harold C. Simmons Comprehensive Cancer Center) ; Krop, Ian E. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Solit, David B. (Memorial Sloan Kettering Cancer Center) ; Mills, Gordon B. (The University of Texas MD Anderson Cancer Center. Present Address: Division of Basic Science Research, Department of Systems Biology) ; Cantley, Lewis C. (Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College) ; Winer, Eric P. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Lin, Nancy U. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Rodon, Jordi (The University of Texas MD Anderson Cancer Center. Present Address: Department of Investigational Cancer Therapeutics) ; Universitat Autònoma de Barcelona
Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. [...]
2020 - 10.1186/s13058-020-01354-y
Breast cancer research, Vol. 22 (november 2020)  
3.
23 p, 4.1 MB Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns / Mateo, Lidia (Institute for Research in Biomedicine (IRB Barcelona)) ; Duran-Frigola, Miquel (Institute for Research in Biomedicine (IRB Barcelona)) ; Gris-Oliver, Albert (Vall d'Hebron Institut d'Oncologia) ; Palafox, Marta (Vall d'Hebron Institut d'Oncologia) ; Scaltriti, Maurizio (MSKCC. Department of Pathology) ; Razavi, Pedram (MSKCC and Weill-Cornell Medical College. Breast Medicine Service, Department of Medicine) ; Chandarlapaty, Sarat (MSKCC and Weill-Cornell Medical College. Breast Medicine Service, Department of Medicine) ; Arribas, Joaquin (Vall d'Hebron Institut d'Oncologia) ; Bellet, Meritxell (Vall d'Hebron Institut d'Oncologia) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ; Aloy, Patrick (Institució Catalana de Recerca i Estudis Avançats (ICREA))
Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. [...]
2020 - 10.1186/s13073-020-00774-x
Genome Medicine, Vol. 12 (september 2020)  
4.
4 p, 1018.1 KB Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation / Cedrés, Susana (Hospital Universitari Vall d'Hebron) ; Felip, Enriqueta (Universitat Autònoma de Barcelona) ; Cruz, Cristina (Hospital Universitari Vall d'Hebron) ; Martinez de Castro, Ana (Hospital Universitari Vall d'Hebron) ; Pardo, Nuria (Universitat Autònoma de Barcelona) ; Navarro, Alejandro (Universitat Autònoma de Barcelona) ; Martinez-Marti, Alex (Universitat Autònoma de Barcelona) ; Remon, Jordin (Vall d'Hebron Institut d'Oncologia) ; Zeron-Medina, Jorge (Hospital Universitari Vall d'Hebron) ; Balmaña, Judith (Universitat Autònoma de Barcelona) ; Llop-Guevara, Alba (Experimental Therapeutic Group) ; Miquel, Josep M (Vall d'Hebron Institut d'Oncologia) ; Sansano, Irene (Pathology Department) ; Nuciforo, Paolo (Molecular Oncology Group) ; Mancuso, Francesco (Cancer Genomic Group) ; Serra, Violeta (Experimental Therapeutic Group) ; Vivancos, Ana (Cancer Genomic Group)
Heat shock proteins (HSPs) are molecular chaperones that maintain proteins in their correct conformation to ensure stability and protect carcinoma cells from apoptosis. HSP90 inhibitors (HSP90i) block multiple targets simultaneously, and despite responses in a selected population, no HSP90i have yet been approved. [...]
2018 - 10.1093/jnci/djy012
JNCI Journal of the National Cancer Institute, Vol. 110 (february 2018) , p. 914-917  
5.
8 p, 473.7 KB RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer / Cruz, C. (Vall d'Hebron Institut d'Oncologia) ; Castroviejo-Bermejo, M. (Experimental Therapeutics Group) ; Gutiérrez-Enríquez, S. (Oncogenetics Group) ; Llop-Guevara, A. (Experimental Therapeutics Group) ; Ibrahim, Y.H. (Experimental Therapeutics Group) ; Gris-Oliver, Albert. (Experimental Therapeutics Group) ; Bonache, S. (Oncogenetics Group) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Bruna, A. (Cancer Research UK Cambridge Institute. University of Cambridge) ; Rueda, O.M. (Cancer Research UK Cambridge Institute. University of Cambridge) ; Lai, Z. (AstraZeneca (USA)) ; Polanska, U.M. (Cancer Research UK. Cambridge Institute) ; Jones, G.N. (Cancer Research UK. Cambridge Institute) ; Kristel, P. (The Netherlands Cancer Institute (NKI) (Netherlands)) ; de Bustos, L. (Experimental Therapeutics Group) ; Guzman, M. (Experimental Therapeutics Group) ; Rodríguez, O. (Experimental Therapeutics Group) ; Grueso, J. (Experimental Therapeutics Group) ; Montalban, G. (Oncogenetics Group) ; Caratú, G. (Cancer Genomics Group) ; Mancuso, F. (Cancer Genomics Group) ; Fasani, R. (Vall d'Hebron Institut d'Oncologia) ; Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ; Howat, W.J. (Cancer Research UK. Cambridge Institute) ; Dougherty, B. (AstraZeneca (USA)) ; Vivancos, A. (Cancer Genomics Group) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Serres-Créixams, X. (Department of Radiology) ; Rubio Rodríguez, Isabel Teresa (Hospital Universitari Vall d'Hebron) ; Oaknin, A. (Vall d'Hebron Institut d'Oncologia) ; Cadogan, E. (Cancer Research UK. Cambridge Institute) ; Barrett, J.C. (AstraZeneca (USA)) ; Caldas, C. (Cambridge University. NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre (UK)) ; Baselga Torres, Josep, 1959-2021, (Memorial Sloan Kettering Cancer Center) ; Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Cortes, Javier (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Jonkers, J. (Cancer Genomics Group) ; Diez, Orland (Hospital Universitari Vall d'Hebron) ; O'Connor, M.J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ; Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210  
6.
39 p, 4.7 MB mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer / Zabala Letona, Amaia (Centro de Investigación Biomédica en Red de Cáncer) ; Arruabarrena Aristorena, Amaia (CIC bioGUNE) ; Martín Martín, Natalia (Centro de Investigación Biomédica en Red de Cáncer) ; Fernández Ruiz, Sonia (Centro de Investigación Biomédica en Red de Cáncer) ; Sutherland, James D. (CIC bioGUNE) ; Clasquin, Michelle (AGIOS Pharmaceuticals) ; Tomás Cortázar, Julen (CIC bioGUNE) ; Jiménez, José (Hospital Universitari Vall d'Hebron) ; Torres Ramírez, Inés Ma. de (Hospital Universitari Vall d'Hebron) ; Quang, Phong (AGIOS Pharmaceuticals) ; Ximénez Embun, Pilar (Centro Nacional de Investigaciones Oncológicas) ; Bago, Ruzica (MRC Protein Phosphorylation and Ubiquitylation Unit) ; Ugalde Olano, Aitziber (Basurto University Hospital) ; Loizaga Iriarte, Ana (Basurto University Hospital) ; Lacasa Viscasillas, Isabel (Basurto University Hospital) ; Unda, Miguel (Basurto University Hospital) ; Torrano, Verónica (Centro de Investigación Biomédica en Red de Cáncer) ; Cabrera, Diana (CIC bioGUNE) ; van Liempd, Sebastiaan M. (CIC bioGUNE) ; Cendon, Ylenia (Universidad Autónoma de Madrid) ; Castro, Elena (Centro Nacional de Investigaciones Oncológicas) ; Murray, Stuart (AGIOS Pharmaceuticals) ; Revandkar, Ajinkya (University of Lausanne) ; Alimonti, Andrea (University of Lausanne) ; Zhang, Yinan (Harvard School of Public Health) ; Barnett, Amelia (AGIOS Pharmaceuticals) ; Lein, Gina (AGIOS Pharmaceuticals) ; Pirman, David (AGIOS Pharmaceuticals) ; Cortázar, Ana R. (CIC bioGUNE) ; Arreal, Leire (CIC bioGUNE) ; Prudkin, Ludmila (Hospital Universitari Vall d'Hebron) ; Astobiza, Ianire (CIC bioGUNE) ; Valcárcel Jiménez, Lorea (CIC bioGUNE) ; Zúñiga García, Patricia (CIC bioGUNE) ; Fernández Domínguez, Itziar (CIC bioGUNE) ; Piva, Marco (CIC bioGUNE) ; Caro Maldonado, Alfredo (CIC bioGUNE) ; Sánchez Mosquera, Pilar (CIC bioGUNE) ; Castillo Martín, Mireia (Fundação Champalimaud) ; Serra, Violeta (Hospital Universitari Vall d'Hebron) ; Beraza, Naiara (CIC bioGUNE) ; Gentilella, Antonio (Institut Català d'Oncologia) ; Thomas, George (Institut Català d'Oncologia) ; Azkargorta, Mikel (Carlos III Networked Proteomics Platform) ; Elortza, Felix (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Farràs, Rosa (Centro de Investigación Príncipe Felipe) ; Olmos, David (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Efeyan, Alejo (Centro Nacional de Investigaciones Oncológicas) ; Anguita, Juan (Ikerbasque) ; Muñoz, Javier (Carlos III Networked Proteomics Platform) ; Falcón Pérez, Juan M. (Ikerbasque) ; Barrio, Rosa (CIC bioGUNE) ; Macarulla Mercadé, Teresa (Hospital Universitari Vall d'Hebron) ; Mato, José M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Martínez Chantar, Maria L. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Cordon Cardo, Carlos (Icahn School of Medicine at Mount Sinai) ; Aransay, Ana M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Marks, Kevin (AGIOS Pharmaceuticals) ; Baselga Torres, Josep, 1959-, (Memorial Sloan Kettering Cancer Center) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Nuciforo, Paolo (Hospital Universitari Vall d'Hebron) ; Manning, Brendan D. (Harvard School of Public Health) ; Marjon, Katya (AGIOS Pharmaceuticals) ; Carracedo, Arkaitz (University of the Basque Country) ; Universitat Autònoma de Barcelona
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation,. Here we show that mTORC1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. [...]
2017 - 10.1038/nature22964
Nature, Vol. 547 (July 2017) , p. 109-113  
7.
12 p, 2.5 MB Cancer network activity associated with therapeutic response and synergism / Serra-Musach, Jordi (Institut Català d'Oncologia) ; Mateo, Francesca (Institut Català d'Oncologia) ; Capdevila-Busquets, Eva (Institut de Recerca Biomèdica de Lleida) ; de Garibay, Gorka Ruiz (Institut Català d'Oncologia) ; Zhang, Xiaohu (National Institutes of Health. Medical Center Dr. Rockville. National Center for Advancing Translational Sciences (NCATS)) ; Guha, Raj (National Institutes of Health. Medical Center Dr. Rockville. National Center for Advancing Translational Sciences (NCATS)) ; Thomas, Craig J. (National Institutes of Health. Medical Center Dr. Rockville. National Center for Advancing Translational Sciences (NCATS)) ; Grueso, Judit (Vall d'Hebron Institut d'Oncologia) ; Villanueva, Alberto (Institut Català d'Oncologia) ; Jaeger, Samira (Institut de Recerca Biomèdica de Lleida) ; Heyn, Holger (Institut d'Investigació Biomèdica de Bellvitge) ; Vizoso, Miguel (Institut d'Investigació Biomèdica de Bellvitge) ; Pérez, Hector (Institut d'Investigació Biomèdica de Bellvitge) ; Cordero, Alex (Institut d'Investigació Biomèdica de Bellvitge) ; Gonzalez-Suarez, Eva (Institut d'Investigació Biomèdica de Bellvitge) ; Esteller, Manel (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; Moreno-Bueno, Gema (Universidad Autónoma de Madrid. Departamento de Bioquímica) ; Tjärnberg, Andreas (Linköping University. Departament of Clinical and Experimental Medicine) ; Lázaro, Conxi (Institut Català d'Oncologia) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Benson, Mikael (Linköping University. Department of Clinical and Experimental Medicine) ; Gustafsson, Mika (Linköping University. Department of Clinical and Experimental Medicine) ; Ferrer, Marc (National Institutes of Health. Medical Center Dr. Rockville. National Center for Advancing Translational Sciences (NCATS)) ; Aloy, Patrick (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; Pujana, Miquel Àngel (Institut Català d'Oncologia)
Cancer patients often show no or only modest benefit from a given therapy. This major problem in oncology is generally attributed to the lack of specific predictive biomarkers, yet a global measure of cancer cell activity may support a comprehensive mechanistic understanding of therapy efficacy. [...]
2016 - 10.1186/s13073-016-0340-x
Genome Medicine, Vol. 8 (August 2016) , ART. 88  

Documentos de investigación Encontrados 3 registros  
1.
245 p, 5.5 MB Caracterización del mecanismo de acción de los pan-inhibidores selectivos del receptor del factor de crecimiento fibroblástico e identificación de potenciales biomarcadores predictivos de respuesta mediante la utilización de xenoinjertos derivados de pacientes con alteraciones en esta vía molecular / Hierro Carbó, Cinta ; Rodón Ahnert, Jordi, dir. ; Serra Elizalde, Violeta, dir. ; Bosch Albareda, Francesc, dir.
En càncer, la desregulació de la via del FGFR:FGF s'ha associat a un creixement tumoral descontrolat, una angiogènesi aberrant i una major capacitat de metastatització. En aquest context, en l'última dècada s'ha fet un gran esforç per desenvolupar fàrmacs dirigits contra aquesta diana terapèutica. [...]
En cáncer, la desregulación de la vía del FGFR:FGF se ha asociado a un crecimiento tumoral descontrolado, una angiogénesis aberrante y una mayor capacidad de metastatización. En este contexto, en la última década se ha realizado un gran esfuerzo en desarrollar fármacos dirigidos contra esta diana terapéutica. [...]
Among cancers, deregulation of the FGFR:FGF pathway has been widely associated with uncontrolled tumoral growth, aberrant angiogenesis and increased metastatic dissemination rates. In this context, several efforts have been done during the last decade in order to develop targeted agents against this molecular pathway. [...]

2020  
2.
7.5 MB ER+ metastatic breast cancer targeted therapy: biomarkers of response and mechanisms of resistance to PI3K and FGFR inhibitors / Sánchez Guixé, Mònica ; Bayascas Ramírez, José Ramón, dir. ; Serra Elizalde, Violeta, dir. ; Graupera i Garcia-Milà, Mariona, dir. ; Rodon Ahrnet, Jordi, dir. ; Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular
La teràpia endocrina és un dels majors avenços en el tractament de càncer de mama (CM) dels últims 30 anys. Tot i això, les pacients acaben recaient degut a mecanismes de resistència, com ara les alteracions de la via de PI3K/mTOR i de FGFR. [...]
Endocrine therapy has been one of the major advances in the treatment of breast cancer (BC) for the past 30 years. However, patients eventually relapse due to mechanisms of resistance. These involve several pathways related to proliferation and growth, including the PI3K/mTOR and FGFR pathways. [...]

[Barcelona] : Universitat Autònoma de Barcelona, 2020.  
3.
203 p, 4.8 MB RAD51 as functional biomarker to select tumors for PARP inhibitor treatment / Castroviejo Bermejo, Marta ; Serra Elizalde, Violeta, dir. ; Martí Ripoll, Mercè, dir. ; Lizcano de Vega, José Miguel, dir. ; Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular
Los inhibidores de la enzima Poly (ADP-ribosa) polimerasa (PARPi) son efectivos en el tratamiento de cánceres que presentan defectos en la reparación del ADN por recombinación homóloga (HRR), incluyendo aquellos con mutaciones en BRCA1 y BRCA2 (BRCA1/2). [...]
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are effective anticancer drugs in cancers with defective homologous recombination DNA repair (HRR), including cancers with mutations in BRCA1 and BRCA2 (BRCA1/2), which also display enhanced sensitivity to DNA damaging chemotherapy such as platinum salts. [...]

[Barcelona] : Universitat Autònoma de Barcelona, 2019.  

Vea también: autores con nombres similares
1 Serra, Víctor
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.